In this episode, Dr. Dave Rabin engages in a thought-provoking conversation with Skippy Mesirow. They delve into the evolving landscape of psychedelic medicine, discussing recent setbacks in the FDA's decision regarding MDMA-assisted therapy and the implications for the broader psychedelic community. Skippy shares his journey as a facilitator in the psychedelic space, offering insights from his work in Colorado's movement and innovative approaches in Aspen. Together, they discuss the vital role of community, compassion, and collaboration in advancing therapies, reflect on the healing and creative energy of Burning Man, and emphasize the importance of unity among advocates for decriminalization and legalization.

Tune in for an inspiring call to action and valuable insights from two dedicated leaders in the field.

What if true healing involves more than just the physical body? Join Dr. Dave Rabin in an inspiring conversation with filmmaker and author Kelly Gores, where they explore the intricate connection between mind, body, and spirit through the transformative potential of psychedelics, spirituality, and self-awareness. They delve into the field of epigenetics, explaining how our environment and experiences can turn genes on and off, directly impacting health outcomes. With powerful stories like Anita Morjani's near-death experience, Kelly illustrates how a change in perception can open pathways to profound healing and connection to our true selves.

This episode also covers the “illusion of separation” that often leads to loneliness and fear, and how psychedelics can help dissolve this barrier, reconnecting us to a sense of universal love and oneness. Kelly shares her own practices of intention-setting and gratitude as transformative tools, showing how each of us holds the power to shape our reality. 

Tune in to uncover how embracing a holistic approach to healing can unlock resilience, empower us to overcome challenges, and bring us back to our authentic selves.

Instagram: https://www.instagram.com/kellygores/
Web: https://www.healwithkelly.co/about.html
Twitter: https://twitter.com/DrDavidRabin
Instagram: https://www.instagram.com/drdavidrabin
Web: https://www.drdave.io/

Learn more about your ad choices. Visit megaphone.fm/adchoices

Is our time quickly becoming the era of “psychedelic McCarthyism”? If we’re not careful, that’s where it looks like we’re heading… In this episode of The Psychedelic Report, Dr. Dave Rabin sits down with Hamilton Morris for an in-depth discussion on the recent controversy surrounding MDMA-assisted therapy and the FDA's pivotal August 9th decision. Together, they address the backlash against MAPS/Lykos and how misinformation has fueled public skepticism and prevented this safe and powerful treatment from getting to millions of patients suffering from PTSD. 

Hamilton shares his experience from evaluation and investigation of the MDMA clinical trials and sheds light on the media's tendency to sensationalize allegations, including claims of misconduct during the trials. Hamilton and Dr Rabin emphasize the importance of relying on the scientific method, evidence-based data, and research, rather than sensationalized narratives, when assessing the safety and efficacy of MDMA-assisted therapy.

The conversation also explores the broader implications of the FDA's ruling and how the negative hype surrounding psychedelics has overshadowed their significant therapeutic benefits and is causing harm to patients in need. They call for a more balanced and responsible approach to discussing these therapies in both journalism and public discourse, advocating for truth and evidence over fear and speculation. 

This episode offers critical insights into the challenges facing psychedelic research today, highlighting the need for thoughtful engagement with the ongoing developments in this field.

In this episode, Dr. Dave Rabin and Dr. Jonathan Edwards tackle the controversial topic of ketamine in light of the tragic death of actor Matthew Perry. Together, they explore the safety profile of ketamine, its legitimate uses in treating depression and suicidal ideation, and dispel misinformation regarding its association with Perry's passing.Dr. Edwards, a leading expert in ketamine-assisted therapy and author of The Revolutionary Ketamine, offers his insights on the pressing need for effective mental health treatments. As suicide rates continue to rise, particularly among young people, this episode emphasizes the potential of ketamine as a life-saving treatment and the importance of therapy in conjunction with medication.Tune in to gain a deeper understanding of ketamine’s role in mental health and how it can potentially save lives.

How do we optimize our bodies and our brains for learning new things? In this episode of The Psychedelic Report, Dr. Dave Rabin welcomes back nutritional biochemist Shawn Wells to explore the often-overlooked topic of post-psychedelic supplementation. They discuss how to optimize the benefits of psychedelic experiences and ensure that the transformations achieved during these journeys can last longer.
 Shawn shares his expertise on various supplements, nutrients, and dietary strategies that can enhance neuroplasticity, support mental health, and promote overall well-being after a psychedelic experience. The conversation covers essential topics such as hydration, the role of adaptogens, the importance of neurotransmitter repletion, and the impact of diet on recovery.
Tune in for valuable insights from leading experts in the field of Psychedelic Medicine.

Optimizing Psychedelic Medicine Experiences with Shawn Wells

In this episode, Dr. Dave Rabin discusses the impact of the FDA's decision, the potential delays in accessing this crucial treatment, and the unethical behavior of certain organizations influencing the FDA. Dr. Rabin is joined by Jon Lubecky, a retired army sergeant and Veteran who took part in MAPS MDMA therapy trials, as he discusses the implications of this rejection and emphasizes the need for ongoing advocacy and hope for eventual approval. The episode also addresses the unethical behavior of Symposia, an organization accused of falsifying information to the FDA to obstruct MDMA therapy approval. Additionally, former Symposia member David Nichols reveals serious ethical violations within the organization, raising questions about their motives and funding. Through these discussions, the episode highlights the critical need for transparency, ethical practices, and continued efforts to ensure access to psychedelic treatments for those in need.
Rachel Nuwer’s Scientific American Article: https://www.scientificamerican.com/article/fdas-rejection-of-mdma-psychotherapy-for-trauma-draws-criticism-from/
Jon Lubecky’s Conversation with David Nickles on Breaking Points: https://www.youtube.com/watch?v=lttFB0c0cAo

Food and Drug Administration5630 Fishers LaneRm. 1061Rockville, MD 20852Docket No. FDA-2024-N-193

Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Dr. Dave Rabin is joined by Dr. John J. Miller, a renowned clinical psychopharmacologist, to discuss the significance of the upcoming FDA decision on MDMA therapy for PTSD.

John J. Miller, M.D. is Medical Director at Brain Health in Exeter, New Hampshire and has served as the Editor-in-Chief for Psychiatric Times since February 2019. He has worked for 38 years as a clinical psychopharmacologist, most recently 17 years as a Staff Psychiatrist at Seacoast Mental Health Center in Exeter, NH. Dr. Miller completed his B.S. in Biochemistry at the University of MA/Amherst. And medical school  and residency in Adult Psychiatry at the University of MA Medical School/Worcester. He is a Diplomate of the American Board of Psychiatry and Neurology. Since 1998 he has presented more than 3,000 lectures throughout the US on a wide range of psychiatric topics including PTSD. You can find Dr. Miller in his monthly editorials for Psychiatric Times that he has been authoring since March 2019.

Discover the history of PTSD treatment, the current limitations of existing medications, and the promising results of MDMA-assisted therapy trials. Learn about the bipartisan support from lawmakers and the urgent need for FDA approval to provide relief to millions suffering from PTSD.

Don't miss this insightful conversation on the potential paradigm shift in mental health treatment. Stay informed and advocate for change by tuning in to The Psychedelic Report.

Brain Health in Exeter, New Hampshire (http://www.brain-health.co)
Psychiatric Times (http://www.psychiatrictimes.com)
https://x.com/PsychTimes?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

https://www.linkedin.com/in/jjmillermd/

https://www.linkedin.com/company/psychiatric-times/

www.apolloneuro.com

FDA petition for MDMA-assisted therapy
https://healingmaps.com/sign-the-petition-to-approve-mdma-therapy/

Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Dr. Dave Rabin MD, PhD is joined by Dr. Geoff Bathje PhD who authored an article published on July 19, 2024 in Chacruna entitled: “The Unbelievable Claims of Psymposia about MAPS and MDMA-Assisted Therapy.”Dr. Bathje and Dr. Rabin discuss the recent FDA Advisory Committee vote on MDMA-assisted therapy for PTSD, which surprisingly and wrongfully concluded that the benefits do not outweigh the risks. This conversation deep dives into Dr. Bathje’s report on how Psymposia, what appears to be a group of fringe radicals, negatively biased the FDA committee's vote on June 4 by writing letters with false and misleading claims in an attempt to prevent the clearance of MDMA for PTSD. Why would anyone not only want to prevent clearance of MDMA therapy for Veterans, but see themselves as heroes for doing so? Find out all that and more in this weeks episode of The Psychedelic Report.


The Unbelievable Claims of Psymposia about MAPS and MDMA-Assisted Therapy by Dr. Geoff Bathje: https://chacruna.net/unbelievable-claims-of-psymposia-about-maps-and-mdma-assisted-therapy/

FDA petition for MDMA-assisted therapy https://healingmaps.com/sign-the-petition-to-approve-mdma-therapy/
Food and Drug Administration5630 Fishers LaneRm. 1061Rockville, MD 20852Docket No. FDA-2024-N-193

Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Psychedelic Report, Jesse Gould, Veteran Army Ranger and Founder of the Heroic Hearts Project, joins Dr. Dave Rabin to explore the implications of the recent FDA advisory committee vote on MDMA-assisted therapy for Veterans with PTSD. They highlight concerns over the influence of non-objective groups on the committee's decision and discuss the potential impact on millions of individuals seeking effective treatment for mental health challenges.
Join the conversation as they explore the implications of disrupting the progress of a groundbreaking treatment and the importance of advocating for evidence-based therapies. Learn how you can get involved and make your voice heard to support the advancement of MDMA-assisted therapy for those who need it most.
To take action and stay informed, visit Heroic Hearts and sign up for updates on upcoming initiatives. Let's come together to ensure access to life-changing treatments for Veterans and individuals suffering from PTSD.
Don't miss this insightful discussion on the intersection of medicine, advocacy, and the future of psychedelic therapies. Subscribe to The Psychedelic Report for more thought-provoking episodes on the latest developments in psychedelic medicine and healing.

FDA petition for MDMA-assisted therapy https://healingmaps.com/sign-the-petition-to-approve-mdma-therapy/

Food and Drug Administration
5630 Fishers Lane
Rm. 1061
Rockville, MD 20852
Docket No. FDA-2024-N-193

In this compelling episode of The Psychedelic Report, Dr. Dave Rabin delves into the evolving landscape of psychedelic-assisted therapies with special guest Jon Lubecki, a veteran and prominent advocate for such treatments in Ukraine. The discussion centers on the recent FDA advisory committee setback, which resulted in a 10 to 1 vote against MDMA-assisted therapy due to lingering concerns about its safety and efficacy, particularly in post-treatment activities like driving. Jon provides a nuanced analysis of the hearing, pointing out significant conflicts of interest among some opponents who failed to disclose their affiliations with competing therapies like psilocybin and ketamine. He also examines the critical role of influential organizations such as ICER and Symposia, whose biased reports have swayed public and regulatory opinions against MDMA trials. With a fervent focus on the broader implications for mental health, especially for veterans suffering from PTSD, Jon underscores the inadequacy of current treatments and the transformative potential of MDMA-assisted therapy. He shares his personal journey from struggling with PTSD to becoming a leading advocate, passionately calling for the democratization of access to these promising therapies, transcending political and social boundaries.

Congressman Dan Crenshaw speaks out on the MDMA-assisted therapy controversy and the anti-Veteran agenda : 
https://www.instagram.com/reel/C8zsu2Wu7M0/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA==

FDA petition for MDMA-assisted therapy https://healingmaps.com/sign-the-petition-to-approve-mdma-therapy/

Food and Drug Administration
5630 Fishers Lane
Rm. 1061
Rockville, MD 20852
Docket No. FDA-2024-N-193

Learn more about your ad choices. Visit megaphone.fm/adchoices